Aarti Drugs

{
  "main_header": {
    "sid": 657348,
    "name": "Aarti Drugs",
    "stock_name": "Aarti Drugs",
    "full_name": "Aarti Drugs Ltd",
    "name_url": "stocks-analysis/aarti-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "375.20",
    "chg": 1,
    "chgp": "0.27%",
    "dir": 1,
    "prev_price": "374.20",
    "mcapval": "3,434.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 524348,
    "symbol": "AARTIDRUGS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE767A01016",
    "curr_date": "Feb 06",
    "curr_time": "",
    "bse_nse_vol": "1.08 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 06, 2026",
    "traded_date_str": "2026 02 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/aarti-drugs-657348-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Aarti Drugs Ltd Declines 1.38% Amid Margin Pressures and Valuation Shifts: 4 Key Factors This Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aarti-drugs-ltd-declines-138-amid-margin-pressures-and-valuation-shifts-4-key-factors-this-week-3826458",
        "imagepath": "",
        "date": "2026-02-07 16:06:03",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>2 Feb:</strong> Stock rises 0.79% despite Sensex decline</p>\n                    <p><strong>3 Feb:</strong> Gains 2.15% as Sensex rallies 2.63%</p>\n                    <p><strong>4 Feb:</strong> Sharp gap down of 9.37% following negative financial trend report</p>\n                    <p><strong>5 Feb:</strong> Valuation metrics upgraded amid ongoing price weakness</p>\n                    <p><strong>6 Feb:</strong> Week closes at Rs.375.20, down 1.38%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.380.45</div></div>\n                    <div class=\"stat-i..."
      },
      {
        "title": "Has Aarti Drugs Ltd declared dividend?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/has-aarti-drugs-ltd-declared-dividend-3823317",
        "imagepath": "",
        "date": "2026-02-05 23:30:56",
        "description": "Aarti Drugs Ltd has declared a dividend.\n\nDividend Details:\n- Percentage announced: 20%\n- Amount per share: 1 per share\n- Ex-date: 09 Feb 26\n\nDividend Yield: 0.27%.\n\nTotal Returns by Period:\nOver the last 3 months, the price return was -25.52%, the dividend return was 0.41%, resulting in a total return of -25.11%.\n\nIn the 6-month period, the price return was -22.09%, the dividend return was 0.41%, leading to a total return of -21.68%.\n\nFor the 1-year period, the price return was -9.88%, the dividend return was 0.49%, culminating in a total return of -9.39%.\n\nOver the 2 years, the price return was -27.88%, the dividend return was 0.57%, resulting in a total return of -27.31%.\n\nIn the 3-year period, the price return was -10.63%, the dividend return was 1.10%, leading to a total return of -9.53%.\n\nFor the 4 years, the price return was -28.55%, the dividend return was 1.10%, culminating in a total return of -27..."
      },
      {
        "title": "Aarti Drugs Ltd Valuation Shifts Signal Changing Market Sentiment",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aarti-drugs-ltd-valuation-shifts-signal-changing-market-sentiment-3821576",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AartiDrugsLtd_valuationdot_3821576.png",
        "date": "2026-02-05 08:01:08",
        "description": "Aarti Drugs Ltd has seen a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, despite a recent downgrade in its overall Mojo Grade to Strong Sell. This nuanced change in price-to-earnings and price-to-book ratios, when analysed against sector peers and historical benchmarks, presents a complex picture for investors navigating the Pharmaceuticals & Biotechnology sector in early 2026."
      },
      {
        "title": "Are Aarti Drugs Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-aarti-drugs-ltd-latest-results-good-or-bad-3821021",
        "imagepath": "",
        "date": "2026-02-04 19:20:07",
        "description": "Aarti Drugs Ltd's latest financial results for Q3 FY26 reflect a complex operational landscape marked by both revenue growth and significant margin compression. The company reported net sales of ₹601.71 crores, which represents a sequential decline of 7.82% compared to the previous quarter, although it shows an 8.10% increase year-on-year. This indicates that while the company is experiencing typical seasonal fluctuations, there is sustained demand for its products across various therapeutic segments.\n\nHowever, the operational challenges are underscored by a notable contraction in the operating profit margin, which fell to 9.15%, the lowest in four quarters. This decline of 376 basis points quarter-on-quarter suggests that rising raw material costs and competitive pressures are impacting profitability. The operating profit before depreciation, interest, and tax decreased significantly by 34.72% sequentially..."
      },
      {
        "title": "Aarti Drugs Ltd Reports Negative Financial Trend Amidst Margin Pressures",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aarti-drugs-ltd-reports-negative-financial-trend-amidst-margin-pressures-3820563",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AartiDrugsLtd_fintrenddot_3820563.png",
        "date": "2026-02-04 11:00:09",
        "description": "Aarti Drugs Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has reported a marked deterioration in its financial performance for the quarter ended December 2025. The company’s recent quarterly results reveal a shift from positive to negative financial trends, with significant contraction in profitability and operating margins, raising concerns among investors and analysts alike."
      },
      {
        "title": "Aarti Drugs Q3 FY26: Margin Pressure Intensifies Despite Revenue Growth",
        "link": "https://www.marketsmojo.com/news/result-analysis/aarti-drugs-q3-fy26-margin-pressure-intensifies-despite-revenue-growth-3820243",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AartiDrugs_quaterlyResult_3820243.png",
        "date": "2026-02-04 09:50:35",
        "description": "Aarti Drugs Ltd., a prominent manufacturer of active pharmaceutical ingredients (APIs), pharma intermediates, and speciality chemicals, reported consolidated net profit of ₹40.54 crores for Q3 FY26, declining 10.47% quarter-on-quarter from ₹45.28 crores in Q2 FY26, though registering a 9.42% year-on-year improvement from ₹37.05 crores in Q3 FY25. The ₹3,331.81 crore market capitalisation company faced significant profitability headwinds during the quarter despite maintaining revenue momentum, with shares plunging 6.80% following the results announcement."
      },
      {
        "title": "Aarti Drugs Ltd Opens with Significant Gap Down Amid Market Concerns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aarti-drugs-ltd-opens-with-significant-gap-down-amid-market-concerns-3820039",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AartiDrugsLtd_gapdown_3820039.png",
        "date": "2026-02-04 09:31:05",
        "description": "Aarti Drugs Ltd commenced trading today with a pronounced gap down, opening at Rs 355, marking a 9.37% decline from its previous close. This sharp drop reflects heightened market concerns following recent developments, resulting in notable volatility and a break in the stock’s prior upward momentum."
      },
      {
        "title": "Are Aarti Drugs Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-aarti-drugs-ltd-latest-results-good-or-bad-3818954",
        "imagepath": "",
        "date": "2026-02-03 19:18:21",
        "description": "Aarti Drugs Ltd's latest financial results for Q2 FY26 reveal a mixed performance characterized by significant year-on-year growth in net sales and net profit, alongside sequential challenges in profitability. The company reported net sales of ₹652.79 crores, reflecting a quarter-on-quarter growth of 10.55% and a year-on-year increase of 9.10%. This growth underscores Aarti Drugs' ability to expand its topline, driven by strong demand across its product portfolios, particularly in antibiotics, anti-inflammatory, and anti-diabetic segments.\n\nHowever, the net profit for the quarter stood at ₹45.28 crores, which indicates a decline of 16.01% compared to the previous quarter, despite a notable year-on-year increase of 29.33%. This sequential decline raises questions regarding the sustainability of profitability, particularly as the PAT margin contracted to 6.92%, down from 9.14% in the prior quarter. The operat..."
      },
      {
        "title": "Aarti Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aarti-drugs-ltd-is-rated-sell-3813987",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AartiDrugsLtd_mojoScore_3813987.png",
        "date": "2026-02-01 10:10:56",
        "description": "Aarti Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 February 2026, providing investors with the most recent and relevant data to assess the company’s outlook."
      }
    ],
    "total": 667,
    "sid": "657348",
    "stock_news_url": "https://www.marketsmojo.com/news/aarti-drugs-657348"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "05-Feb-2026",
      "details": "Newspaper Publication of Financial Results",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "04-Feb-2026",
      "details": "Intimation of Investors Conference",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "04-Feb-2026",
      "details": "Recording of earning conference call",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Aarti Drugs Ltd has declared <strong>20%</strong> dividend, ex-date: 09 Feb 26",
          "dt": "2026-02-09",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Aarti Drugs Ltd has announced <strong>3:1</strong> bonus issue, ex-date: 30 Sep 20",
          "dt": "2020-09-30",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Aarti Drugs Ltd Declines 1.38% Amid Margin Pressures and Valuation Shifts: 4 Key Factors This Week

2026-02-07 16:06:03

Key Events This Week

2 Feb: Stock rises 0.79% despite Sensex decline

3 Feb: Gains 2.15% as Sensex rallies 2.63%

4 Feb: Sharp gap down of 9.37% following negative financial trend report

5 Feb: Valuation metrics upgraded amid ongoing price weakness

6 Feb: Week closes at Rs.375.20, down 1.38%

Week Open

Rs.380.45

Read full news article

Has Aarti Drugs Ltd declared dividend?

2026-02-05 23:30:56

Aarti Drugs Ltd has declared a dividend. Dividend Details: - Percentage announced: 20% - Amount per share: 1 per share - Ex-date: 09 Feb 26 Dividend Yield: 0.27%. Total Returns by Period: Over the last 3 months, the price return was -25.52%, the dividend return was 0.41%, resulting in a total return of -25.11%. In the 6-month period, the price return was -22.09%, the dividend return was 0.41%, leading to a total return of -21.68%. For the 1-year period, the price return was -9.88%, the dividend return was 0.49%, culminating in a total return of -9.39%. Over the 2 years, the price return was -27.88%, the dividend return was 0.57%, resulting in a total return of -27.31%. In the 3-year period, the price return was -10.63%, the dividend return was 1.10%, leading to a total return of -9.53%. For the 4 years, the price return was -28.55%, the dividend return was 1.10%, culminating in a total return of -27...

Read full news article

Aarti Drugs Ltd Valuation Shifts Signal Changing Market Sentiment

2026-02-05 08:01:08

Aarti Drugs Ltd has seen a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, despite a recent downgrade in its overall Mojo Grade to Strong Sell. This nuanced change in price-to-earnings and price-to-book ratios, when analysed against sector peers and historical benchmarks, presents a complex picture for investors navigating the Pharmaceuticals & Biotechnology sector in early 2026.

Read full news article

Are Aarti Drugs Ltd latest results good or bad?

2026-02-04 19:20:07

Aarti Drugs Ltd's latest financial results for Q3 FY26 reflect a complex operational landscape marked by both revenue growth and significant margin compression. The company reported net sales of ₹601.71 crores, which represents a sequential decline of 7.82% compared to the previous quarter, although it shows an 8.10% increase year-on-year. This indicates that while the company is experiencing typical seasonal fluctuations, there is sustained demand for its products across various therapeutic segments. However, the operational challenges are underscored by a notable contraction in the operating profit margin, which fell to 9.15%, the lowest in four quarters. This decline of 376 basis points quarter-on-quarter suggests that rising raw material costs and competitive pressures are impacting profitability. The operating profit before depreciation, interest, and tax decreased significantly by 34.72% sequentially...

Read full news article

Aarti Drugs Ltd Reports Negative Financial Trend Amidst Margin Pressures

2026-02-04 11:00:09

Aarti Drugs Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has reported a marked deterioration in its financial performance for the quarter ended December 2025. The company’s recent quarterly results reveal a shift from positive to negative financial trends, with significant contraction in profitability and operating margins, raising concerns among investors and analysts alike.

Read full news article

Aarti Drugs Q3 FY26: Margin Pressure Intensifies Despite Revenue Growth

2026-02-04 09:50:35

Aarti Drugs Ltd., a prominent manufacturer of active pharmaceutical ingredients (APIs), pharma intermediates, and speciality chemicals, reported consolidated net profit of ₹40.54 crores for Q3 FY26, declining 10.47% quarter-on-quarter from ₹45.28 crores in Q2 FY26, though registering a 9.42% year-on-year improvement from ₹37.05 crores in Q3 FY25. The ₹3,331.81 crore market capitalisation company faced significant profitability headwinds during the quarter despite maintaining revenue momentum, with shares plunging 6.80% following the results announcement.

Read full news article

Aarti Drugs Ltd Opens with Significant Gap Down Amid Market Concerns

2026-02-04 09:31:05

Aarti Drugs Ltd commenced trading today with a pronounced gap down, opening at Rs 355, marking a 9.37% decline from its previous close. This sharp drop reflects heightened market concerns following recent developments, resulting in notable volatility and a break in the stock’s prior upward momentum.

Read full news article

Are Aarti Drugs Ltd latest results good or bad?

2026-02-03 19:18:21

Aarti Drugs Ltd's latest financial results for Q2 FY26 reveal a mixed performance characterized by significant year-on-year growth in net sales and net profit, alongside sequential challenges in profitability. The company reported net sales of ₹652.79 crores, reflecting a quarter-on-quarter growth of 10.55% and a year-on-year increase of 9.10%. This growth underscores Aarti Drugs' ability to expand its topline, driven by strong demand across its product portfolios, particularly in antibiotics, anti-inflammatory, and anti-diabetic segments. However, the net profit for the quarter stood at ₹45.28 crores, which indicates a decline of 16.01% compared to the previous quarter, despite a notable year-on-year increase of 29.33%. This sequential decline raises questions regarding the sustainability of profitability, particularly as the PAT margin contracted to 6.92%, down from 9.14% in the prior quarter. The operat...

Read full news article

Aarti Drugs Ltd is Rated Sell

2026-02-01 10:10:56

Aarti Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 February 2026, providing investors with the most recent and relevant data to assess the company’s outlook.

Read full news article

View All News